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INTRODUCTION 
Sexual dysfunction affects a couple’s relationship and the quality 
of life of the patient and the partner irrespective of age.   Lower Urinary 
Tract Symptoms suggestive of BPH is highly prevalent among the 
elderly. So too are the symptoms of sexual dysfunction in old age. But the 
symptoms of sexual dysfunction are not concentrated upon, both by the 
patient and the physician at least in our country. Sexual dysfunction 
manifests mainly as erectile dysfunction (ED), ejaculatory disorders, or 
decreased libido/hypoactive sexual desire (HSD). Men with moderate-to-
severe LUTS are at increased risk for sexual dysfunction. Though 
reduced rigidity and reduced ejaculate volume are the highly prevalent 
symptoms in ageing men, reduced rigidity and pain on ejaculation are 
considered to be most bothersome, affecting the quality of life. 
Sexual dysfunction is much more prevalent in patients with 
LUTS/BPH than in men without them, even after controlling for 
confounding variables such as age and co morbid illnesses. Hence 
LUTS/BPH is considered to be an independent risk factor for sexual 
dysfunction. 3 The reason for the association being a common underlying 
pathology or the psychological effect of LUTS / BPH on sexual function 
needs to be confirmed. Despite a decline in the frequency of sexual 
intercourse, as well as in overall sexual functioning, most elderly men 
report regular sexual activity and consider their sex life as an important 
dimension of their quality of life (QoL). However, most patients with 
LUTS/BPH experience a negative effect of LUTS on their sex life. 
  2
Hence, treatment of LUTS/BPH should also aim to at least maintain or, if 
possible, improve sexual function. 2  
The successful management of patients with LUTS associated with 
BPH should include assessments of sexual function and monitoring of 
medication-related sexual side effects. For men with LUTS and sexual 
dysfunction, an appropriate integrated management approach, based on 
each patient's symptoms and outcome objectives, is warranted. 1 
 We intended to evaluate the prevalence of sexual dysfunction in 
the LUTS/BPH patient population in our country, in our set-up to analyze 
the amount of importance attached to the sexual quality of life and also to 
see the correlation between LUTS and sexual dysfunction. 
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AIM & OBJECTIVES 
To evaluate the prevalence of sexual dysfunction in LUTS/BPH 
patients. 
To assess the effect of LUTS/BPH effect on sexual function. 
To assess the treatment effect of LUTS/BPH on sexual function.  
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REVIEW OF LITERATURE 
Prevalence of BPH / LUTS     
From the historic times, symptoms of LUT were considered to be 
part and parcel of normal aging process. The definite relation between 
aging and LUTS was not evaluated clearly till 1984. In 1984 meta- 
analysis by Berry and colleagues summarized the data from five studies 
demonstrating that no men younger than 30 had evidence of BPH and the 
prevalence rose with each age group, peaking at 88% in men in their 80s. 
The prevalence increases rapidly in the fourth decade of life, reaching 
nearly 100% in the ninth decade. It is striking that the age-specific 
autopsy prevalence is remarkably similar in all populations studied 
regardless of ethnic and geographic origin  
Clinical Prevalence  
The definition of BPH, has undergone several changes in the past 
decade, and, at present, no single criterion can be applied. In the past, the 
term “prostatism” was used, incorrectly referring to the prostate as the 
sole source of the typical LUTS found in aging men. It has been pointed 
out that there are at least three interrelated phenomena that can be 
assessed independently, namely the symptoms (formerly called 
prostatism), enlargement of the prostate gland, and presence of 
obstruction. In a given patient, all three, two of the three, or only one of 
the three entities might be present. Paul Abrams coined the term lower 
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urinary tract symptoms to replace the old and inappropriate term 
prostatism 4. When evaluating elderly men, one can therefore stratify 
them by the level of LUTS into mildly, moderately, and severely 
symptomatic according to a standardized symptom severity and 
frequency questionnaire 5. The same patients then can be further 
classified based on the degree of prostatic enlargement as measured by 
digital rectal examination (DRE), transrectal ultrasonography (TRUS), or 
magnetic resonance imaging (MRI) and finally by the presence and 
degree of bladder outlet obstruction as measured by flow rate recordings 
or invasive pressure flow studies.  
 Of all men older than 40, a certain proportion develop histologic 
hyperplasia of the prostate, that is, BPH. Of those, some but not all 
develop LUTS, and other may have LUTS for reasons other than BPH 
(e.g., urethral stricture, stones, inflammation). Prostate enlargement 
occurs in some but again not all men with histologic BPH and LUTS, and 
some men with enlarged glands may not have any symptoms at all. 
Urodynamically proven obstruction may be present in all the combination 
groups of men who have one, several, or all of histologic BPH, LUTS, 
and enlarged glands, yet others may have obstruction without having any 
evidence of BPH (e.g., urethral stricture, prostate cancer, primary bladder 
neck sclerosis). In addition to the mere enumeration of symptoms by 
frequency of occurrence, the bother associated with the symptoms, 
interference with activities of daily living, and the impact of the 
symptoms on quality of life are important distinguishing characteristics.  
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When studying the prevalence of clinical BPH—admittedly an 
imprecise term describing the constellation of LUTS, bother, interference, 
quality of life impact, with or without enlargement, obstruction, and so 
forth—disease definitions may be applied that take either one or several 
of these items into consideration. Thus, rather than describing truly the 
prevalence of a disease in populations, one can describe the distribution 
of certain attributes of such disease in different populations stratified by 
age. 
Symptom Severity and Frequency  
The development, validation, and translation with cultural and 
linguistic validation of the standardized, self-administered seven-item 
American Urological Association (AUA) symptom index (also known as 
the International Prostate Symptom Score [I-PSS]) has been a pivotal 
event in the clinical research on LUTS and BPH 5. With the total score 
running from 0 to 35 points, patients scoring 0 to 7 points are classified as 
mildly symptomatic, those scoring from 8 to 19 points as moderately 
symptomatic, and those scoring 20 to 35 points as severely symptomatic.  
This instrument is an integral part of virtually every epidemiologic 
study as well as treatment studies in the field, and the availability of 
validated translations in many common languages allow cross-cultural 
comparisons of unprecedented scope. Socioeconomic factors do not seem 
to influence responses to the questionnaire, and fundamentally similar 
  7
responses are obtained when the questionnaire is self-administered, read 
to the patient, mailed in, or administered in some other way 6. However, 
there is no question that subtle differences in comprehension of the 
translated questionnaire as well as different perception of the symptoms, 
willingness to admit to the symptoms, and other factors are the cause for 
cross-cultural differences in symptom severity reported in the literature. 
        A very large international investigation of LUTS in Asian men was 
undertaken by Homma and colleagues (1997) in which 7588 men from 
Japan, China, Taiwan, Korea, the Philippines, Thailand, Singapore, 
Pakistan, India, and Australia were queried. The finding of 18%, 29%, 
40%, and 56% of men in their 40s, 50s, 60s, and 70s having moderate to 
severe symptoms was in line with the other studies reported both from 
Asia and from Europe and North America. In addition to the major 
community-based studies listed, other studies have been published with 
similar findings but often done under less stringent conditions. Despite 
the significantly different proportion of men admitting to moderate to 
severe symptoms, a clear trend toward an increase in symptom scores 
with advancing age is noticeable in all reported studies.  
Prevalence of sexual dysfunction in aging men & LUTS patients 
The results of several recent large-scale studies have shown a 
consistent and strong relationship between LUTS and both ED and EjD. 
It appears that the pathophysiological mechanisms of LUTS and the 
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related prostatic enlargement of BPH as well as certain treatments for this 
condition may have an impact on both the erection and ejaculation 
components of the sexual response. 
Epidemiological studies 
MMAS (Massachusetts Male Aging Study) 
The MMAS was a community based, random sample observational 
survey of men 40 to 70yrs old conducted from 1987-1989  in Boston MA. 
A self administered sexual activity questionnaire was used to assess the 
erectile potency7. The MMAS documented that ED is a highly prevalent 
disorder that frequently coexists with other risk factors, both medical and 
psychosocial. The 8 year longitudinal survey that followed  MMAS 
clearly showed that ED increases with age.                  
Cologne Male Survey 
The Cologne Male Survey was conducted in a similar fashion. In 
this study instead of considering the percentage of incidence, odds ratio 
was calculated 8. The study showed LUTS have a risk ratio of 2.11 in 
patients with ED. 
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 The Multinational Survey of the Aging Male (MSAM-7)  
The Multinational Survey of the Aging Male (MSAM-7) was 
conducted in the United States and 6 European countries in 12,815 men 
aged 50-80 years. It investigated the relationship between LUTS and 
sexual dysfunction in aging men by mailed questionnaiirre. International 
Prostate Symptom Score, the Danish Prostatic Symptom Score, and the 
International Index of Erectile Function and a health and demographics 
questionnaire were used. 
The results were consistent from one country to another. Sexual 
activity was reported by 83% of the sample, with 71% reporting at least 
one episode of sexual activity during the previous 4 weeks. Sexual 
disorders and their bother were strongly related to both age and severity 
of LUTS. The relationship between sexual problems and LUTS is 
independent of co-morbidities such as diabetes, hypertension, cardiac 
disease, and hypercholesterolemia.  The major finding was that LUTS 
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severity is a major risk factor for sexual dysfunction (both erection and 
ejaculation problems) independent of other risk factors (Figures 1 and 2). 
 
Figure 1. Multinational Survey of the Aging Male-7: sexual activity 
declines with increasing severity of lower urinary tract symptoms 
independent of age. 
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Figure 2. Multinational Survey of the Aging Male-7: prevalence of 
ejaculatory dysfunction (EjD) increases with severity of lower urinary 
tract symptoms independent of age 
With these results it was concluded that Sexual activity is common 
in a majority of men over age 50 and is an important component of 
overall quality of life. The presence and severity of LUTS are 
independent risk factors for sexual dysfunction in older men.  
Epidemiological studies summary 
It appears from epidemiological data that there is a global 
correlation between LUTS and erectile dysfunction. Little evidence 
supporting the connection was available until the mid-1990s, when 
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several epidemiological studies assessing the prevalence of BPH and 
associated quality-of-life issues suggested that LUTS by themselves 
could affect sexual function. Later, many authors reported an association 
between LUTS and various aspects of sexual dysfunction. The link 
between LUTS and sexual dysfunction was unambiguously confirmed by 
the Multi-National Survey of the Ageing Male-7.  Hence, 
epidemiological studies provide clear evidence that LUTS and sexual 
dysfunction, including ED and abnormal ejaculation, are strongly linked. 
However, a causal relationship between LUTS and sexual dysfunction 
cannot be established based on these data alone, as the underlying 
pathophysiological mechanisms need to be determined.  
Potential causes of sexual dysfunction; 
The underlying mechanism may be physiological, 
pathophysiological or psychological. 
Erectile dysfunction; 
The causal relationship between ED and LUTS can be explored 
using Hill's causality method, which separates causal from non-causal 
explanations. This establishes a link using general epidemiological data, 
case-control reports, and cohort studies grounded by a supportive 
plausible mechanism of action. The epidemiological data are examined 
for the strength of association (relative risk), consistency (replication of 
findings), dose–response effect and temporal relationship (effect of onset 
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or cessation of LUTS on ED and vice versa). Moreover, even if there is a 
link between ED and LUTS from an epidemiological perspective, then 
the causal relationship must be shown to have biological plausibility 
before any widespread acceptance is possible. Four theories supporting 
biological plausibility currently exist 10 . 
The NOS/NO theory 
This hypothesis attempts to explain the link between ED and LUTS 
by the reduced production of NOS/NO in the pelvis, which includes the 
penis, bladder and prostate. NO is a multifunctional molecule originally 
described as a vasodilator. The NOS/NO theory suggests that reduced 
NOS/NO results in smooth muscle cell proliferation, which may result in 
structural changes in the prostate and simultaneous increased contraction 
which affects outlet resistance and bladder compliance, leading to  
LUTS. 11 
Autonomic hyperactivity and metabolic syndrome 
It was also proposed that LUTS secondary to BPH is a part of the 
metabolic syndrome, which includes glucose intolerance, insulin 
resistance, obesity, dyslipidaemia and hypertension, all known risk 
factors for ED12,13. Manipulation of the autonomic innervation of the 
pelvis has a profound effect on prostate growth and differentiation 14. 
Increased autonomic nervous system activity has been shown to induce 
BPH in ageing rats, and ED 15. Concordant evidence also comes from 
observations in spontaneously hypertensive rats that develop autonomic 
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hyperactivity, prostate hyperplasia and ED, and have increased voiding 
frequency and detrusor overactivity16. Altered responses to corpus 
cavernosum nerve stimulation and smooth muscle contraction in these 
rats correlate with ED17. 
In humans, autonomic nervous system hyperactivity is also 
associated with signs and symptoms of LUTS secondary to BPH. 
McVary et al. 18 as part of the MTOPS study, evaluated the autonomic 
nervous system activity in 38 men before enrolment. Tilt-table testing (a 
measure of autonomic tone and reactivity) revealed that increased 
sympathetic tone (as measured by changes in blood pressure, heart rate, 
urinary and serum catecholamine levels) was significantly associated with 
the level of LUTS even when controlled for cofactors known to influence 
the sympathetic tone (age, body mass index, abdominal obesity, C-
peptide and insulin levels, physical inactivity). Further analyses showed 
that autonomic hyperactivity was strongly related to the total IPSS, the 
BPH Impact Index and the bother score (IPSS question 8) and to a lesser 
extent to the total prostate volume and transitional zone volume. 
Increased Rho-kinase activation/endothelin activity 
Smooth muscle contraction has been attributed to an increase in the 
intracellular calcium concentration. The Rho-kinase pathway is likely to 
regulate smooth muscle tone in conditions in which tonic contraction or 
high basal tone is involved 19. Increased Rho-kinase activity, and 
consequently increased calcium sensitivity of the contractile machinery, 
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can be found in the detrusor or corpus cavernosum of rabbits with partial 
BOO or diabetes, and in vascular smooth muscle in hypertension. The 
actions of several factors beside noradrenaline (e.g. endothelin-1, 
angiotensin II), possibly involved in the increased smooth muscle activity 
found in both LUTS/BPH and sexual dysfunction, are dependent on Rho-
kinase activity that acts downstream from these receptors 20. It is 
therefore tempting to speculate that the common link between LUTS and 
sexual dysfunction is increased Rho-kinase activity. 
Pelvic atherosclerosis 
There is a high prevalence of vascular risk factors (hypertension, 
diabetes, hypercholesterolaemia, smoking) in elderly men, suggesting the 
possible involvement of atherosclerosis in the aetiology of BPH. Chronic 
ischaemia is associated with an increased production of TGF-β1 that 
correlates with the severity of fibrosis. It also impairs neurogenic 
relaxation in the prostate, which appears to involve the NO pathway, and 
may result in a loss of elasticity and increase in smooth muscle tone of 
the prostate 21.  
Post treatment effect 
Although surgery, minimally invasive therapies, and 
pharmacologic therapies can all improve LUTS and the peak urinary flow 
rate, some can cause or exacerbate ED (incidence rates: surgery, 10%; 
minimally invasive therapies, 1%–3%; pharmacologic monotherapy or 
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combination therapy, 3%–10%) and EjD (incidence rates: surgery, 65%; 
minimally invasive therapies, 4%–16%; pharmacologic monotherapy or 
combination therapy, 0%–10%) 22. 
Impact of medical therapies for BPH on sexual function 
5α-reductase inhibitors 
The 5α-reductase inhibitors (finasteride, dutasteride) act by 
inhibiting the conversion of testosterone to 5α-dihydrotestosterone 
(DHT). They are recommended for treating LUTS in men with large 
prostates. There is evidence from randomized controlled trials and meta-
analyses that finasteride and dutasteride are equally effective in reducing 
prostatic size, serum PSA level and serious outcomes such as acute 
urinary retention and the need for BPH-related surgery. Side-effects of 
5α-reductase inhibitors are related to sexual function and include 
decreased libido, erectile dysfunction (ED and ejaculatory dysfunction 
(EjD) 23,24,25. Gynaecomastia is also more frequent than with placebo. 
Hence, in a recent meta-analysis by the AUA, finasteride, an inhibitor of 
the type II 5α-reductase isoenzyme, was associated with a greater 
incidence of ED (8%), decreased libido (5%) and EjD (4%) than with 
placebo (4%, 3% and 1%, respectively). The sexual side-effect profile of 
dutasteride, a novel inhibitor of both type I and type II 5α-reductase 
isoenzymes appears closely similar to that of finasteride. In a pooled 
analysis of three double-blind placebo-controlled studies which included 
4325 men aged ≥ 50 years and with BPH, dutasteride administered for 
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2 years was associated with a significantly higher incidence of ED 
(7.3%), decreased libido (4.2%), gynaecomastia (2.3%) and EjD (2.2%) 
than was placebo (4.0%, 2.1%, 0.7% and 0.8%, respectively). Moreover, 
in a direct comparative study of 1-year duration which included 1630 
patients with LUTS, dutasteride and finasteride showed comparable 
incidences of ED (7% vs 8%, respectively), decreased libido (5% vs 6%), 
EjD (1% vs 1%) and gynaecomastia (1% vs 1%) 
The pathophysiology of increased sexual dysfunction with 5α-
reductase inhibitors is not known precisely, but might be related to the 
reduction in DHT.   
α1-adrenergic blockers 
It is well established that all α1-adrenoceptor blockers currently 
recommended for treating LUTS (alfuzosin, doxazosin, tamsulosin, 
terazosin) have an equal clinical effectiveness, producing a mean 4–
6 point improvement in the IPSS 23. However, they differ in their side-
effect profile. In the AUA meta-analysis, while the four α1-adrenoceptor 
blockers showed incidences of decreased libido (1–3%) and ED (3–5%) 
closely similar to placebo (3% and 4%, respectively), tamsulosin was 
associated with a higher incidence of EjD (10%) than the other α1-
adrenoceptor blockers (0–1%) and placebo (1%). The higher incidence of 
EjD, based of patients’ spontaneous reports in clinical trials, is dose-
related. Hence, in a 3-month placebo-controlled study conducted in the 
USA, the incidence of abnormal ejaculation with tamsulosin increased 
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from 6% with the 0.4 mg dose to 18% with the 0.8 mg dose, while no 
patient receiving placebo reported EjD. The incidence of EjD while on 
tamsulosin may also increase over time, as shown in long-term extensions 
of phase III clinical studies. Over a 53-week treatment period, abnormal 
ejaculation was reported by 10% and 26% of patients with the 0.4 mg and 
0.8 mg doses of tamsulosin, respectively. Over a mean duration of 
treatment of 64.5 weeks, 30% of patients treated with tamsulosin (0.4–
0.8 mg per day) reported abnormal ejaculation. 
To try to elucidate the pathophysiological mechanism of EjD 
associated with α1-adrenoceptor blockers, a double-blind, placebo-
controlled, crossover study (ABnormal EJACulation with alfuzosin and 
tamsulosin, ABEJAC) compared the effects on ejaculation of placebo, 
alfuzosin 10 mg once daily and tamsulosin 0.8 mg once daily in 48 
healthy volunteers aged 18–36 years, and having a normal sexual 
function documented by the International Index of Erectile Function 26. 
The trial was divided into three treatment periods, so each subject 
received each treatment once (placebo, alfuzosin and tamsulosin) for 
5 days, with each treatment period separated by a 10-day washout period. 
The 0.8 mg dose of tamsulosin was chosen to ensure an evaluable 
incidence of EjD, in this first mechanistic study ever conducted on such a 
topic. The primary endpoints of the study were the amount of ejaculate 
volume after masturbation (and after abstaining from sexual activity for ≥ 
48 h), and sperm concentration in the urine after ejaculation. The mean 
(sd) ejaculate volume at baseline was 3.4 (1.4) mL. Tamsulosin markedly 
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decreased the ejaculate volume, by −2.4 (0.17) mL, compared to 
alfuzosin, at + 0.3 (0.18) mL (P < 0.001 vs tamsulosin) and placebo, at + 
0.4 (0.18) mL (P < 0.001 vs tamsulosin; not significant vs alfuzosin). 
There was a decrease in ejaculate volume of >20% in 90% of subjects 
during tamsulosin treatment, compared to 21% with alfuzosin (P < 0.001 
vs tamsulosin) and 12.5% with placebo (P < 0.001 vs tamsulosin, not 
significant vs alfuzosin). Moreover, 35% of subjects had no ejaculation 
with tamsulosin, compared to none while on alfuzosin or placebo. This 
reduced or absent ejaculation was not due to retrograde ejaculation, as 
confirmed by the absence of an increased sperm count in urine samples 
(changes in urine sperm concentration, 106/mL, were + 1.4 with placebo, 
+ 1.2 with alfuzosin, and + 1.7 with tamsulosin; between group p = ns  
The ABEJAC study thus confirmed that a functioning bladder neck 
has no role in the different effects of alfuzosin and tamsulosin on 
ejaculatory function. Similar conclusions were drawn from a pilot study 
conducted in 17 Japanese healthy male urologists 27. They received, in a 
crossover protocol, tamsulosin 0.2 mg and 0.4 mg once daily over 3 days, 
followed by measurements of the amount of ejaculate and sperm 
concentration in midstream urine samples after ejaculation, each ejaculate 
being obtained after 3 days of abstinence. The amount of ejaculate was 
significantly lower with both doses of tamsulosin, at 1.75 (1.3) mL with 
the 0.2 mg dose and 1.64 (1.6) mL with the 0.4 mg dose, compared to 
controls, at 3.21 (1.2) mL. There was a reduction in ejaculation volume of 
>80% from baseline in a third of the volunteers. There was no sperm in 
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midstream urine samples after ejaculation in any of the volunteers before 
or after tamsulosin, confirming that the objective reduction in ejaculate 
volume was not due to retrograde ejaculation. 
There is thus evidence that tamsulosin causes dose-dependent 
reduction in the amount of ejaculate and that it starts objectively from the 
0.2 mg dose. The underlying mechanism is not retrograde ejaculation. 
Several additional hypotheses have been postulated. 
Mechanisms of impaired ejaculation with Tamsulosin 
The ejaculation process includes two distinct phases: (i) The 
emission phase involves secretion of seminal fluids from the accessory 
sex glands and contraction of the seminal tract from the epididymis to the 
prostate. This is associated with a strong closure of the bladder neck as 
soon as the emission starts, to prevent retrograde ejaculation; (ii) The 
expulsion phase involves rhythmic contractions of the striated perineal 
muscles (particularly the bulbospongiosus smooth muscle) with 
involvement of the urethral smooth musculature, which expel the semen 
from the prostatic urethra to the urethral meatus. Two different 
hypotheses, peripheral and central, have been currently suggested to 
explain the observed impairment of ejaculation with tamsulosin. 
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Peripheral hypothesis 
α1A-adrenoceptors are widely distributed in all the organs 
participating in the emission phase (epididymis, vas deferens, seminal 
vesicle, prostate gland, prostatic urethra and bladder neck). This means 
that α1A-adrenoceptors play a role in the emission phase of ejaculation. 
Tamsulosin, which is the only α1-adrenoceptor blocker showing some α1A 
selectivity, may affect this first phase of ejaculation. 
In a study , increased seminal vesicle pressure, mimicking the 
emission phase of ejaculation, was induced in anaesthetized Wistar rats 
by electrical stimulation of the hypogastric nerve, before and after an i.v. 
injection with vehicle or tamsulosin (3 and 10 µg/kg) or alfuzosin (3 and 
10 µg/kg). Both doses of tamsulosin significantly decreased the 
contraction of the seminal vesicle, while both doses of alfuzosin had only 
marginal effects on it. Because the seminal vesicle is the major 
contributor to the volume of semen, such an effect of tamsulosin is likely 
to reduce significantly the amount of ejaculate volume. A limitation of 
the study was that the dose levels used (identical for both drugs) may not 
have appropriately reflected those used in clinical practice 28.  . 
In another study, the effects of alfuzosin (10 µg/kg, i.v) and 
tamsulosin (3 µg/kg, i.v) were tested on the contractions of the 
epididymal and prostatic portions of the rat vas deferens, induced either 
by noradrenaline or by nerve stimulation. Tamsulosin and alfuzosin 
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significantly differed in their effects on epididymal and prostatic portions 
of the vas deferens, i.e. tamsulosin was associated with an abnormal 
increase in the contractions of prostatic portions of the vas deferens, 
which is likely to alter the progression and emission of sperm. There was 
no such effect with alfuzosin. 
Central hypothesis 
Both the brain and spinal cord are crucial in triggering the emission 
and expulsion phases of ejaculation. Electrical recordings from the 
bulbospongiosus muscle contractions occurring during expulsion in 
humans showed that electrical activity during ejaculation is highly 
organized 29. Delivery of 8-OH-DPAT, a 5HT1A and D2-like agonist, to 
the brain of anaesthetized male rats produces organized electrical activity 
in the bulbospongiosus muscle, mimicking what happens during the 
expulsion phase of ejaculation 30. 
This can therefore be used as an experimental model to investigate 
the central control of ejaculation. A central effect is therefore plausible, 
as tamsulosin has a strong affinity for 5HT1A and D2-like receptors, both 
of which are involved in the central control of ejaculation. 
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AUA meta-analysis of outcomes of medical therapies: estimates of 
occurrence of sexual adverse events - Adapted from (31) 
Therapy 
Median % (95% CI) problems with 
Ejaculation Erection Libido 
α-blockers 
  Alfuzosin – 3 (1–6) 1 (0–4) 
  Doxazosin 0 (0–2) 4 (1–8) 3 (2–6) 
  Tamsulosin 10 (6–15) 4 (1–8)  
  Terazosin 1 (1–2) 5 (3–8) 3 (1–5) 
Hormonal 
  Finasteride 4 (3–5) 8 (6–11) 5 (4–7) 
Combined 
  Alfuzosin/finasteride 1 (0–2) 8 (5–11) 2 (1–4) 
  Doxazosin/finasteride 3 (2–6) 10 (7–14) 3 (1–5) 
  Terazosin/finasteride 7 (5–10) 9 (1–13) 5 (3–8) 
  Placebo 1 (1–1) 4 (3–5) 3 (3–4) 
Minimally invasive therapy 
The effects of open prostatectomy, transurethral resection, 
transurethral vaporization, doxazosin and finasteride on sexual functions 
of men were investigated in a total of 305 patients with benign prostatic 
hyperplasia. The sexual functions of the patients were assessed with a 
questionnaire before treatment and 3 and 6 months after the treatment. A 
total of 212 (70%) patients were judged to be potent before the treatment. 
At 3 months, open prostatectomy and transurethral resection caused 
erectile dysfunction in 2 of 40 (5%) and 5 of 89 (6%) potent patients, 
respectively. At 6 months, one of the patients from the former and 2 of 
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the patients from the latter groups who developed erectile dysfunction at 
3 months stated improvement. Transurethral vaporization caused loss of 
erectile functions in 4 of 14 potent patients (29%) at the 3-month follow-
up and, one of these patients recovered erectile functions at 6 months. 
Only one of the 33 patients (3%) using doxazosin stated that he lost his 
erectile functions both at 3 months and 6 months. At 3 months follow-up, 
finasteride caused loss of erectile functions in 8 of 36 potent patients 
(22%). Four of these patients underwent surgery (transurethral resection) 
after 3 months of finasteride use. At the 6-month follow-up, 4 more 
patients suffered from loss of erectile functions 32. 
The mean probability of a patient becoming impotent following a 
transurethral resection of the prostate (TURP) would be approximately 
13.6% with a 90% confidence interval of 3.4% to 32.4%. This needs to be 
considered in the context of a 4.3% erectile dysfunction rate following an 
unrelated general surgical procedure, undoubtedly attributable to a 
“sham” effect. The AHCPR Guideline suggested that further research was 
needed to determine the “number of patients who subsequently developed 
impotence, ejaculatory dysfunction, incontinence, and drug-related side 
effects” following treatment. 33  
The belief that TURP could be responsible for erectile dysfunction 
based on relatively poor evidence from uncontrolled studies published 
prior to 1994 was shattered in 1995 by the publication of data from a VA 
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Cooperative Study comparing the outcomes of TURP and watchful 
waiting in 556 men with moderate LUTS. In this study, TURP was not 
associated with changes in either general well-being, social activities, or 
sexual performance (P=0.92). In fact, at the end of the 3-year study, 19% 
of patients in the surgery group and 21% of those in the watchful waiting 
group reported that their sexual performance was worse, while 3% in 
each group reported it was improved. In general, the spouses or partners 
thought that the patients’ sexual performance was unaffected over the 
course of the study 34. 
Sexual Function Following High Energy Microwave Thermotherapy  
In a study35, 147 patients were randomized to either undergo TURP 
or transurethral microwave thermotherapy (TUMT) using a high energy 
protocol. Patients were given a self-administered questionnaire before the 
treatment and 3 and 12 months after the treatment. While LUTS 
improved in both treatment groups, the magnitude of the improvement 
was clearly greater in the TURP group compared with the TUMT group. 
However, at 3 months, only 27% of the TURP group had ante grade 
ejaculation compared with 74% of the TUMT group. These numbers 
were unchanged at the 1-year follow-up point. One can therefore state 
that approximately two-thirds of men will suffer retrograde ejaculation 
following TURP versus only one-third of men following high energy 
microwave thermotherapy. Changes in sexual function were experienced 
in 36% of patients undergoing TURP versus 17% undergoing TUMT. 
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Patients were asked regarding their overall satisfaction with sexual 
function, and it was noted that, in the TUMT group, 76% were either very 
satisfied or satisfied prior to treatment versus 81% after 3 months. In the 
TURP group, 69% were either very satisfied or satisfied before treatment 
versus 85% following treatment. Problems with erection were reported in 
20% of the TUMT and 17% of the TURP-treated patients. 
Evaluation of sexual function or dysfunction 
Questionnaires and Sexual Function Symptom Scores  
Many male sexual function profiles and ED questionnaires have 
been developed. Formerly, the aim of these detailed questionnaires was to 
differentiate psychogenic from nonpsychogenic ED. More recently, a 
variety of self-report measures for assessing the levels of male sexual 
function or dysfunction have been described; self-administered 
questionnaires (SAQs) have seen their greatest use in clinical trials. SAQs 
provide quantifiable efficacy endpoints for new drug trials; they attempt 
to quantify sexual interest, performance, and satisfaction. Those most 
commonly referred include the International Index of Erectile Function 
(IIEF) 36  ,  Brief Male Sexual Function Inventory (BMSFI) , Dysfunction 
Inventory for Treatment Satisfaction (EDITS). Other self-report measures 
include the Derogatis Sexual Function Inventory (245 items), the Center 
for Marital and Sexual Health Questionnaire (18 items), and the recently 
added Male Sexual Function Scale (Rosen R) 37. 
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The BMSFI instrument covers sexual drive (2 items), erection (3 
items), ejaculation (2 items), perceptions of problems in each area (3 
items), and overall satisfaction (1 item). The EDITS questionnaire is very 
useful in drug studies; Ultimately, in the clinic, satisfaction rates are 
established by prescription refills, dropouts, and requests for further 
evaluation 
The IIEF is the most widely used SAQ, and it is statistically 
validated in many languages. Its 15 items address and quantify five 
domains: erectile function, orgasmic function, sexual desire, intercourse 
satisfaction, and overall satisfaction.  
In the hope of providing physicians with a “checklist” on erectile 
function that could be used in an office setting, an abridged 5-item 
version of the IIEF-15 has been developed 38, in which 4 items are taken 
from the erectile function domain. The fifth item addresses sexual 
intercourse satisfaction; it was chosen to reflect the central element in the 
NIH Consensus Panel (1992) definition of ED, which ties erectile 
function to satisfaction: “maintain erection of sufficient rigidity and 
duration to permit satisfactory sexual performance.” Perhaps the most 
important difference between the IIEF-15 and the IIEF-5 is that the latter 
asks patients to self-assess erectile function and satisfaction over the past 
6 months, a more clinically relevant and practical time frame than 4 
weeks. ED severity is classified into five categories based on the IIEF-5: 
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severe (5 to 7), moderate (8 to 11), mild to moderate (12 to 16), mild (17 
to 21), and no ED (22 to 25). 
The Male Sexual Function Scale was developed in conjunction 
with the Second International Consultation on Sexual Dysfunction is 
based on qualitative research in normal and sexually dysfunctional men 
and assesses core components of male sexual function (desire, erection, 
ejaculation, satisfaction) in both clinical and research settings. The scale 
was designed by an independent advisory board of experts in male 
sexuality, without involvement or funding from industry. This new 
screening tool is suitable for use in both primary care and urology 
practice settings and may be valuable in screening patients for sexual 
dysfunction after pelvic surgery or with chronic illness or medications 
One major drawback of sexual inventories is their reliance on self-
assessment. Blander and coworkers (1999) have demonstrated that SAQs 
do not differentiate among the various causes of ED (arterial, venous, or 
mixed vascular), and evidence-based assessments (diagnostic tests) are 
still necessary in patients with complex ED.  
Treating patients with ED and BPH/LUTS 
α1-Adrenergic blockers and ED 
Selective α1-adrenergic blockers relax smooth muscle cells in the 
bladder neck, prostatic urethra and prostatic stroma . Alfuzosin, 
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doxazosin, tamsulosin and terazosin are all considered appropriate α1-
adrenergic blockers for treating LUTS suggestive of BPH 39. They do not 
affect libido or erectile function, and could even have, in some cases, a 
positive effect on ED  
Clinical studies 
Sexual dysfunction is a concern in hypertensive patients because 
antihypertensive medication is an important risk factor for ED. The 
Treatment of Mild Hypertension Study (TOMHS) examined the effects of 
various antihypertensive agents on sexual function 40. Overall, 902 
patients (557 men and 345 women) aged 45–69 years with stage 1 
diastolic hypertension were randomized to receive placebo or one of five 
active drugs (acebutolol, amlodipine, chlorthalidone, doxazosin, 
enalapril) over 48 months. At baseline, 14.4% of men reported ED 
problems. The incidences of ED during the follow-up were 9.5% and 
14.7% at 24 and 48 months, respectively, and were related to the type of 
antihypertensive treatment. When compared with other active treatments, 
the incidence of ED was lowest in the doxazosin group, although the 
difference vs placebo was not statistically significant. In addition, 
disappearance of erection problems among men with problems at baseline 
was greatest for men treated with doxazosin. 
Another α1-adrenergic blocker, alfuzosin 10 mg once daily, 
administered for 1 year in 3076 men with LUTS suggestive of BPH, also 
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gave significant improvements from baseline in both ED and EjD 
(reduced ejaculation and painful ejaculation) assessed by the DAN-
PSSsex These improvements were particularly marked in men with 
severe LUTS or severe bother at enrolment. Moreover, alfuzosin 10 mg 
once daily administered for 2 years in 799 men with LUTS also 
significantly improved from baseline all domains of the Brief Sexual 
Function Inventory (BSFI), including sexual drive (P < 0.05), erectile 
function (P < 0.05), ejaculation (P < 0.05), bother associated with sexual 
problems (P < 0.05) and overall satisfaction with sex life (P < 0.001). 
Once again, improvements were greater in men with severe LUTS at 
baseline. 
Phosphodiesterase-5 (PDE-5) inhibitors and LUTS 
Clinical studies 
In a pilot study 41, 111 patients with ED attending an andrology 
outpatient clinic were offered oral sildenafil ‘on demand’ and reviewed 
after 1 and 3 months of treatment. They completed the IIEF and the IPSS 
questionnaires at baseline and at each visit after inclusion. At enrolment, 
67% of men had mild LUTS, 26% moderate LUTS and 6% severe LUTS. 
Under sildenafil treatment, both the IPSS and bother score severity 
improved from baseline. Moreover, men with a lower LUTS or bother 
score at baseline had higher (i.e. better) IIEF scores after 3 months of 
treatment. Nitric oxide (NO) and PDE-5 isoenzymes have been identified 
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in the human prostate. The improvement of LUTS with sildenafil might 
thus be mediated by increased NO activity, resulting in smooth muscle 
cell relaxation. Placebo-controlled studies are currently ongoing with two 
different PDE-5 inhibitors, sildenafil and tadalafil, to confirm their 
possibly beneficial effect in the treatment of LUTS. 
Combined α1-Adrenergic blockers and PDE-5 inhibitors for treating 
LUTS and ED 
Clinical studies 
Currently, very few studies have evaluated the effect on LUTS and 
ED of combining an α1-adrenergic blocker with a PDE-5 inhibitor. In a 
retrospective analysis of 42 men with ED, considered nonresponders to 
tadalafil monotherapy, the addition of an α1-adrenergic blocker (alfuzosin 
10 mg once daily) to tadalafil (20 mg on demand), improved ED in 71% 
of patients  42. The side-effect profile was similar to that of tadalafil 
monotherapy and there were no significant alterations in blood pressure 
(BP). The possibly synergistic effect of both medications can be 
explained by their different mechanisms of action. Alfuzosin, by blocking 
α1-adrenergic receptors and reducing the sympathetic tone in penile 
smooth muscle and prostate/bladder neck, could enhance the vasoactive 
influence of tadalafil, that acts through the NO pathway. Here again, 
placebo-controlled studies are needed to confirm these results. 
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Safety profile 
Due to the strong association between LUTS and sexual 
dysfunction, the co-prescription of drugs treating both LUTS and ED is 
increasing. As both α1-adrenergic blockers and PDE-5 inhibitors can have 
a slight impact on BP, physicians were concerned about possible 
haemodynamic interaction between these classes of drugs. 
Clinical considerations when treating ED and BPH/LUTS 
Given a common cause, the effective management of ED and 
BPH/LUTS is a regimen of mutually beneficial agents. However, the 
safety profile of each drug, especially the effect on the cardiovascular 
system for α1-adrenergic blockers, must be considered in the final choice 
of drugs to be combined. Doxazosin was associated with a particularly 
low incidence of ED in men with hypertension (TOHMS)  and might 
have a beneficial effect in patients who failed to respond to agents 
specifically formulated to improve ED 43. Thirty-eight men with moderate 
to severe ED who failed to respond to an intracavernosal injection with 
alprostadil, a synthetic prostaglandin-E1 agent, received doxazosin 
titrated to 4 mg daily over 3 weeks, combined with intracavernosal 
alprostadil on demand. Overall, 58% of patients had a significant (>60%) 
improvement in the IIEF. Alfuzosin 10 mg once daily has been shown to 
improve ED and EjD, as assessed by the DAN-PSSsex and BSFI 
questionnaires, in men with LUTS, and to improve ED in combination 
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with tadalafil, in nonresponders to tadalafil monotherapy. Tamsulosin has 
also been found to have some benefit on sexual quality of life in men with 
BPH/LUTS, although it can be associated with EjD. α1-adrenergic 
blockers can also be safely used with PDE-5 inhibitors, with which they 
might act synergistically. 
The 5α-reductase inhibitors are used to treat patients with LUTS 
and prostatic enlargement, and can be associated with ED, low libido, and 
decreased ejaculatory volume. They can be used concomitantly with 
PDE-5 inhibitors. 
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MATERIALS & METHODS 
Between June 2007 and November 2007, all patients admitted into our 
ward with LUTS/BPH were included for evaluation. These patients were 
admitted for either evaluation or intervention for LUST/ BPH. 
• Informed consent obtained from all eligible patients. 
• All patients after admission were given the linguistic version of 
IPSS & MSHQ 
• Pts who are literate were asked to fill up the questionnaire. (Self 
administered questionnaire) 
• Pts who were not able to fill up (for various reasons like illiterate, 
poor eye sight, not able to understand the contents) were 
interviewed personally. 
• To avoid interviewer bias, the same interviewer interviewed all pts. 
• All details regarding the pts demographics, scoring, results will be 
entered into a proforma  
• Post treatment effect evaluation was done at the end of 3 months 
following treatment. 
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Initial evaluation; 
The patients with complaints suggestive of LUTS/ BPH were 
thoroughly evaluated with  
History & Physical examination, 
DRE & Focused neurological examination,  
Baseline blood parameters,  
USG KUB, Uroflow & PVR. 
Inclusion criteria 
1. All patients with history suggestive of LUTS/BPH with more than 
50 years were included. 
2. Patients who gave informed consent for the study were included. 
Exclusion criteria 
After the initial evaluation the patients were excluded using the following 
exclusion criteria. 
1. Patients who have been already treated for LUTS / BPH earlier. 
2. Patients with co-morbid illness like DM & HT. 
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3. Patients with history or clinical examination suggestive of 
associated neurological disorder. 
4. Patients who were not willing to self-administer the questionnaire 
or to be interviewed. 
Symptom severity & Sexual function assessment 
All the patients were given with the linguistic version of the 
International - Prostate Symptom Score ( I - PSS).  
Sexual function assessment was done using linguistic version of 
the Male sexual Function Scale. The Male Sexual Function Scale consists 
a total of 8 questions of which two questions are on erectile function 
domain & its bother and three are on ejaculatory function domain & its 
bother, one question each on sexual desire and satisfaction.  The final 
question assessed the overall bother or distraction of life due to the sexual 
dysfunction.    
The linguistic conversion was done by the investigator with the 
help of a Psychologist who had experience in interviewing such type of 
patients. At most care was taken in phrasing the words so that it should 
not be embarrassing to the patient. Before put into use in this clinical 
study, the questionnaire was circulated among out patients who were 
waiting for ultrasound examination. They were asked to comment on the 
content whether it is understandable or not, and their suggestions were 
taken.  
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The investigator interviewed patients (78 patients – 65%) who are 
illiterate and who could not read the questionnaire because of poor 
eyesight and who could not understand the content. To avoid bias, the 
same investigator interviewed all such patients. In all other patients ( 42 
patients –35 %)  it was used as a self-administered questionnaire (SAQ). 
Management 
Management of these patients was done according to the institute’s 
protocol. Management consisted of medical therapy in the form of α- 
blockers and 5AR Inhibitors. Surgical therapy was mainly Transurethral 
resection of prostate (TURP) 
Post treatment evaluation 
Evaluation following treatment was done at the end 3rd month. All 
patients were asked to come for follow-up at the end of 3rd month and 
were given the I-PSS & Male sexual function scale questionnaires. 
Uroflow with post void residue was also done to ascertain the effect of 
therapy.  
Correlation between LUTS & Sexual dysfunction; 
Correlation between LUTS severity and sexual function severity 
was assessed using Microsoft Excel correlation coefficient. 
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RESULTS & OBSERVATION 
All the patients who were admitted in our hospital for either 
evaluation (or) intervention of LUTS / BPH in the time period between 
July 2007 & December 2007 were enrolled for the study. After initial 
evaluation, 112 patients were excluded from the study as per exclusion 
criteria adopted.  
Total enrolled  232 
Co-morbid illness(DM /HT) 76 
Already treated 16 
No consent  20 
Total Excluded 112 
Included in study 120 
 
 The major cause for exclusion was associated co-morbid illnesses 
(Diabetes Mellitus or Hypertension (76 pts)). Finally 120 patients were 
included in the study. 
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Age stratification 
Age  group NO % 
50 – 59 23 19.1 
60 – 69 73 60.8 
70-79 23 19.1 
> 80 1 0.8 
 
The mean age of the patients is 64.5, in the range between 53 and 
82. The majority (73) were in the age group of 60 – 69.  
LUTS severity stratification 
LUTS severity and bother No % 
Mild  16 13.33 
Moderate  40 33.33 
Severe  64 53.33 
Total 120 100 
 
Most of the patients (64, 53.33%) had severe bothersome symptoms  
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Age group-wise LUTS severity 
 Mild Moderate Severe Total 
50 - 59 9 9 5 23 
60 - 69 4 27 42 73 
70-79 3 4 16 23 
> 80 0 0 1 1 
Total 16 40 64 120 
               
Most of the patients in the 50 to 59 age group (78%) had mild or 
moderately severe symptoms. In the 60-69 group 94.5% of patients had 
bothersome moderate to severe symptoms. Severe degree of symptoms 
were present in most of the patients in the 70 – 79 age group.  
Prevalence of sexual dysfunction 
Erectile dysfunction 
 No % 
None  29 24% 
Moderate 60 50% 
Severe 31 26% 
Total 120 100 
 
Most of the patients (50%) had moderate bother due to their 
erectile dysfunction. The rest had either no or severe bother in equal 
number.                                     
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Age Group 1 2 3 Grand Total 
50-59 14 7 2 23 
60-69 9 40 24 73 
70-79 5 13 5 23 
80-89 1   1 
Grand Total 29 60 31 120 
 
64 out of 73 patients in the age group of 60 moderate to severe 
erectile dysfunction, whereas, only 9 out of 14 patients had significant 
dysfunction in the age group of 50 – 59. The correlation coefficient for 
age and LUTS score is 0.33, signifying a positive correlation. As age 
increases the incidence of LUTS also increases. 
Ejaculatory dysfunction 
 No % 
No / mild 80 67% 
Moderate 39 32% 
Severe 1 1% 
Total 120 100% 
     
Majority (66.6%) of the 120 patients had either no or mild bother 
due to their ejaculatory function. Only 1 was severely bothered. 
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Age Group 1 2 3 Grand Total 
50-59 22 1  23 
60-69 46 26 1 73 
70-79 11 12  23 
80-89 1   1 
Grand Total 80 39 1 120 
 
Just one patient in the age group of 50 -59 had significant 
ejaculatory dysfunction, whereas, 28 out of 96 patients above 60 yrs had 
significant ejaculatory dysfunction. 
Sexual desire disorder 
 No % 
No / Mild 72 60% 
Moderate 41 34% 
Severe 7 6% 
Total 120 100 
 
       Majority of patients (60%) were not at all bothered by their sexual 
desire disorder. 7 patients (6%) were severely bothered by their sexual 
desire disorder. 
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Sexual satisfaction                        
 No % 
Full sat. 50 41% 
Mild dis 34 28% 
Mod dis 29 25% 
Total dis 7 6% 
Total 120 100% 
 
Among the 120 patients 50 (41 %) were fully satisfied with their 
sexual activities. Around 30% of patients were either moderately 
dissatisfied or totally dissatisfied. 
Over all bother / distraction due to sexual dysfunction 
Bother No % 
None 36 29 
Very Mild  7 6 
Mild 29 24 
Moderate 20 17 
Severe 28 24 
Total 120 100 
 
Among the 120 patients 28 (23.3%) were very much bothered 
about sexual dysfunction. 20 patients (16.6%) were moderately bothered 
about their sexual dysfunction. Majority of patients (30%) not at all 
bothered about their sexual dysfunction. 
  44
Age Group 1 2 3 4 5 
Grand 
Total 
50-59 2 2 5  14 23 
60-69 23 17 18 4 11 73 
70-79 3 1 6 3 10 23 
80-89     1 1 
Grand Total 28 20 29 7 36 120 
 
 58 out of 73 patients in the age group 60 – 69 had bothersome 
sexual dysfunction.  25 out of 47 patients felt no bother due to sexual 
dysfunction in the other age groups.                      
Correlation between LUTS severity and sexual dysfunction bother      
LUTS and Erectile dysfunction 
LUTS No / Mild Moderate Severe Total 
Mild 16 0 0 16 
Moderate 12 27 1 40 
Severe 1 33 30 64 
Total 29 60 31 120 
        
 All Patients with mild LUTS symptoms had none or mild erectile 
dysfunction, almost all of the patients in the severe LUTS group had 
moderate or severe erectile dysfunction.  
 The correlation coefficient is 0.71 showing significant positive 
correlation between LUTS and erectile dysfunction. 
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LUTS and Ejaculation 
LUTS No / Mild Moderate Severe Total 
Mild 16 0 0 16 
Moderate 35 5 0 40 
Severe 29 34 1 64 
Total 80 39 1 120 
 
 Only the patients with severe LUTS had ejaculatory dysfunction, 
34 out of 40 patients.  
The correlation coefficient is 0.5 
LUTS and sexual bother 
 None Very 
Mild 
Mild Moderate Severe Total 
Mild 16 0 0 0 0 16 
Moderate 13 5 14 7 1 40 
Severe 7 2 15 13 27 64 
Total 36 7 29 20 28 120 
 
None of the patients with mild LUTS symptoms were bothered by 
sexual dysfunction. Around 30% of patients with moderate LUTS had 
mild bother. 45% of patients with severe LUTS had severe distress due to 
sexual dysfunction. 
The correlation coefficient is 0.65, significant positive correlation. 
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Treatment given 
Treatment No % 
Medical 16 13% 
Surgical 104 87% 
Total 120 100% 
 
After baseline evaluation among the 120 patients only 16 patients 
(13.3%) were eligible or willing to undergo medical therapy. 
Patients (8) who had prostate volume of less than 30 cc were 
started on α blockers. 8 patients had prostate volume of more than 30 cc 
and they were advised to take combination therapy (α - blockers & 5-
ARIs).  
Medical Treatment 
α - blockers 8 
5-ARIs 0 
Both 8 
Total 16 
 
All patients had significantly improved flow rate and consequent 
reduction in I- PSS score. 
  47
Sexual function assessment  
 Pre treatment Ej.D Post Treatment Ej.D 
Mild Mod Sev Mild Mod Sev 
α - blockers 8 0 0 6 2 0 
Both  8 0 0 4 4 0 
Total 16 0 0 10 6 0 
 
The erectile function was not altered after medical therapy. 6 
patients (38%) developed bothersome ejaculatory dysfunction after 
medical therapy. 50% of patients on combined therapy and 25% on α - 
blockers alone had ejaculatory dysfunction. 
Surgical therapy 
Surgical therapy was mainly in the form of TURP. 104 patients 
underwent TURP under suitable anaesthesia. All patients had smooth 
postoperative period. All patients were asked to come for follow up at the 
end of 3 months. Only 34 pts turned up for repeat evaluation.  
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          ED Ej.D 
Mild Mod Sev Mild Mod Sev 
Pre Op 11 16 7 28 6 0 
Post Op 11 9 14 8 20 6 
     
Post operatively among the 16 patients who had moderate bother 7 
patients (20%) had worsening of their erectile problems. Rest of the 
patients perceived no change. 
Among the 28 patients who had no problems with ejaculatory 
function pre op, 20(71%) developed moderately bothersome ejaculatory 
dysfunction postoperatively. All the 6 patients who had moderate bother 
progressed to severe bother postoperatively. 
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DISCUSSION 
Lower urinary tract symptoms suggestive of benign prostatic 
hyperplasia (LUTS/BPH), and sexual dysfunction, are common, highly 
bothersome conditions in older men, and the prevalence of both disorders 
increases with age. Sexual dysfunction manifests mainly as erectile 
dysfunction (ED), ejaculatory disorders (EjD), or decreased 
libido/hypoactive sexual desire (HSD). Men with moderate-to-severe 
LUTS are at increased risk for sexual dysfunction. The successful 
management of patients with LUTS associated with BPH should include 
assessments of sexual function and monitoring of medication-related 
sexual side effects. For men with LUTS and sexual dysfunction, an 
appropriate integrated management approach, based on each patient's 
symptoms and outcome objectives, is warranted. MSAM-7 study showed 
that there is progressive increase in LUTS and sexual dysfunction with 
age and independent increase in sexual dysfunction in patients with 
LUTS. 
Out of a total of 232 patients who were enrolled into the study, 120 
were finally included in the study after applying the inclusion and 
exclusion criteria. Though the sample size appears low, the patient group 
is the hospitalized patients only that form those who are very much 
distressed with the symptoms. Moreover the sample size is comparable 
with that of Namasivayam (et al)44.  Patients with co-morbidities were 
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excluded from the study. They formed around one third of the patients. It 
is important to note that 10% of patients refused to respond to sexual 
health questionnaire, which carries significance. 
 The mean age of the patients was 65.8. The predominant age group 
is 60 – 69 yrs. This age characteristic is comparable to the studies in the 
literature. The elderly age may be significant, because age as such can 
have a bearing on sexual dysfunction as revealed in the Cologne Male 
Survey. 
 More than half of the patients had severe LUTS. This may be due 
to the patient sample selected, i.e. the in patient group. The LUTS 
symptoms also had age wise variation, with 78% of those in the 50 – 59 
age group with mild symptoms, and most of them in the 70 – 79 group 
with severe symptoms. This signifies increase in prevalence with age. 
 The sexual function too showed variation among different age 
groups. Both the factors, the erectile dysfunction and ejaculatory 
dysfunction were more common in the age group of 60 – 69, compared to 
other age groups. Only the patients in the age group 60 -69 were 
significantly bothered by sexual dysfunction. This may be due to the 
association of sexual dysfunction with increasing age. Moreover patients 
after the age of 70 years may not consider their sexual dysfunction 
bothersome, though they have a high prevalence. 
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 None of the patients in the mild LUTS group had ED whereas 98% 
in the severe group and 70% in the moderate LUTS group had significant 
ED. The increasing age is associated with both increase in LUTS and ED. 
This correlates well with the reports of the MSAM –7.  The correlation 
coefficient for LUTS with ED is 0.71, which is highly significant. It is 
similar to the world literature. 
  The ejaculatory function was not that frequently affected By 
LUTS compared with ED. 67% of patients had no effect on their 
ejaculatory function regardless of their LUTS status. Whereas, in those 
affected, more than 90 % belonged to the severe LUTS group. This shows 
that though severe LUTS may not always associated with ejaculatory 
dysfunction, the presence of ejaculatory dysfunction signifies a higher 
LUTS status. These results correlate well with the study by Rosen RC et 
al who propose a prevalence of 70 –80 % sexual dysfunction with LUTS. 
The correlation coefficient is 0.5, signifying effective positive correlation. 
 The degree to which the patients are bothered by their sexual 
dysfunction also varies well with LUTS. Almost all the patients (27/28) 
who had severe bother due to sexual dysfunction had associated severe 
LUTS. None of them had mild LUTS. 30% of the patients with LUTS 
had no bothersome sexual dysfunction. This includes patients in the 
higher age group strata who may have significant dysfunction, but may 
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not be bothered by it. Around 89% of patients with severe LUTS had 
bothersome sexual dysfunction. 
This bears evidence to the fact that sexual dysfunction increases 
with increasing LUTS. The MSAM –7 showed that the incidence of 
bothersome sexual dysfunction associated with LUTS. The correlation 
coefficient is 0.65, which shows that as LUTS increases, so too sexual 
dysfunction hand in hand requiring simultaneous effective management. 
 In the Government institutional set up, with predominantly poor 
patients, the standard medical management could not be given to the 
majority of the patients as they cannot afford it. So around 90% of the 
patients were taken up for TURP. Another problem with our patients is 
the poor compliance and lack of follow up. This is proved by the fact that 
only 34 out of 104 patients came for follow up after TURP. 
  In the post treatment evaluation after medical therapy, the 
ejaculatory function decreased in around 36% of the patients. This can be 
expected because retrograde ejaculation is one of the commonest adverse 
effect as associated with alpha blockers.27 There was no change in the 
erectile function after medical therapy. 
 Out of the 34 patients who came for follow up after TURP, 20% of 
patients in the moderate ED progressed to severe ED. This may be due to 
the thermal injury to cavernosal nerves caused by TURP. 70% of the 
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patients developed ejaculatory dysfunction post operatively. This is also 
well explained in the literature. 
 To conclude, sexual dysfunction is highly prevalent in the patients 
with LUTS in the range of 70%. The age group should also be taken into 
consideration, because increasing age as such can lead to sexual 
dysfunction. As we do not have a control group we were unable to signify 
the influence of age. The severity of LUTS also correlated with severity 
of sexual dysfunction. The treatment outcome is not promising as the 
patients’ ejaculatory dysfunction increased with both surgery and medical 
management. Though the sample size is small and the follow up is 
limited, we can suggest that treatment of sexual function should be 
combined with management of sexual dysfunction for better patient 
satisfaction. 
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CONCLUSION 
The prevalence of sexual dysfunction in patients with LUTS is 
70%. 
The severity of sexual dysfunction correlates with severity of 
LUTS. 
Ejaculatory function deteriorates after treatment of LUTS/BPH. 
SUGGESTIONS 
All patients with LUTS should be evaluated for sexual dysfunction 
Treatment of sexual dysfunction should be combined with LUTS 
management for better patient satisfaction and quality of life.  
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MASTER CHART 
S.No. Age LUTS DRE LUTS score ED EjD Desire Satisfaction Bother Treatment
Post treatment 
ED Ej D 
1 75 6 mo Gr I Severe 2 2 2 2 1 TURP   
2 60 4 mo Gr II Severe 2 2 1 3 1 TURP 2 2 
3 70 6 mo Gr I mild 1 1 1 1 5 TURP   
4 60 8 mo Gr II Mod 2 1 1 1 3 TURP 2 1 
5 75 6 mo Gr II Severe 2 1 2 4 1 TURP   
6 78 8 mo GR I mild 1 1 1 1 5 TURP 1 1 
7 55 5 mo GR II Severe 3 1 1 1 1 TURP 3 1 
8 65 6 mo GR II Severe 2 2 2 2 2 TURP 3 2 
9 53 7 mo GR II Severe 3 1 1 1 2 TURP 3 1 
10 60 6 mo GR I Mod 2 1 1 1 3 TURP   
11 80 5mo GR III Severe 1 1 1 1 5 TURP 1 1 
12 57 4 mo GR I Mod 2 1 1 1 3 TURP   
S.No. Age LUTS DRE LUTS score ED EjD Desire Satisfaction Bother Treatment
Post treatment 
ED Ej D 
13 75 1 yr GR II Severe 2 1 2 3 3 TURP 3 1 
14 61 8 mo GR I Mod 1 1 1 1 5 TURP 1 1 
15 64 11 mo GR I Severe 2 1 1 1 3 TURP   
16 60 5 mo GR II Mod 2 2 1 2 2 TURP   
17 58 9 mo GR I mild 1 1 1 1 5 Medical 1 2 
18 55 7 mo GR I Severe 2 1 1 1 3 TURP   
19 75 1 yr GR II Severe 2 2 2 2 5 TURP   
20 60 7 mo GR I Mod 2 1 1 2 3 Medical 2 1 
21 55 6 mo GR I Mod 1 1 1 1 5 TURP   
22 75 18 mo GR II Severe 2 2 2 2 3 TURP 2 3 
23 58 8 mo GR I Severe 2 2 1 3 2 TURP   
24 53 9 mo GR I Mod 1 1 1 1 5 TURP 1 1 
25 77 1 yr GR II mild 1 1 1 1 5 TURP   
26 60 5 mo GR I Mod 2 1 2 2 2 TURP 2 2 
S.No. Age LUTS DRE LUTS score ED EjD Desire Satisfaction Bother Treatment
Post treatment 
ED Ej D 
27 72 8 mo GR III Severe 2 2 2 3 3 TURP   
28 57 6 mo GR I mild 1 1 1 1 5 Medical 1 1 
29 78 18 mo GR III Severe 2 1 2 3 4 TURP 2 2 
30 65 10 mo GR II Severe 2 1 1 1 3 TURP 2 2 
31 65 4 mo GR I mild 1 1 1 1 5 Medical 1 2 
32 60 6 mo GR I mild 1 1 1 1 5 Medical 1 2 
33 74 11 mo GR II Severe 1 1 1 1 5 TURP 1 2 
34 69 1 yr GR I Severe 2 2 2 1 3 TURP   
35 60 6 mo GR I Mod 2 1 1 2 3 Medical 2 2 
36 65 9 mo GR II Severe 2 2 2 4 1 TURP 2 3 
37 65 10 mo GR II Severe 2 1 1 2 2 TURP   
38 78 1 yr GR II Mod 2 1 1 1 5 TURP   
39 64 8 m0 GR I Severe 3 2 2 3 1 TURP 3 3 
40 70 18 mo GR II Mod 2 1 2 2 3 TURP   
S.No. Age LUTS DRE LUTS score ED EjD Desire Satisfaction Bother Treatment
Post treatment 
ED Ej D 
41 63 5 mo GR I Mod 2 1 1 2 2 TURP 3 2 
42 66 7 m0 GR II Severe 2 1 2 2 1 TURP   
43 60 6 mo GR I Severe 2 1 3 3 1 TURP   
44 71 1 yr GR II Mod 2 1 1 1 5 TURP 2 2 
45 59 3 mo GR I mild 1 1 1 1 5 Medical 1 2 
46 68 18 mo GR II Mod 2 1 1 3 3 TURP   
47 63 6 mo GR I Mod 2 2 2 2 2 TURP   
48 70 10 mo GR III Severe 2 2 1 2 4 TURP   
49 58 4 mo GR I mild 1 1 1 1 5 Medical 1 1 
50 66 5 mo GR II Severe 3 2 3 3 2 TURP 3 3 
51 57 6 mo GR I Mod 2 1 1 2 3 Medical 2 2 
52 68 8 mo GR II Severe 2 1 2 2 2 TURP   
53 67 18 mo GR II Severe 3 2 2 2 2 TURP   
54 78 9 mo GR II Mod 1 1 1 1 5 TURP 1 2 
S.No. Age LUTS DRE LUTS score ED EjD Desire Satisfaction Bother Treatment
Post treatment 
ED Ej D 
55 69 8 mo GR III Severe 3 2 2 3 3 TURP   
56 65 6 mo GR I Mod 1 1 1 1 5 TURP 1 2 
57 58 4 mo GR I mild 1 1 1 1 5 TURP 1 2 
58 68 9 mo GR II Severe 2 2 2 3 1 TURP 2 2 
59 64 11 mo GR II Severe 2 1 2 3 1 TURP 3 2 
60 63 8 mo GR II Severe 2 1 1 2 3 TURP   
61 60 6 mo GR I Mod 2 1 2 2 2 TURP   
62 58 5 mo GR I mild 1 1 1 1 5 Medical 1 1 
63 70 18 mo GRII Severe 3 2 2 2 1 TURP   
64 68 4 mo GR II Severe 3 2 1 2 2 TURP   
65 59 6 mo GR I Mod 1 1 1 1 5 TURP   
66 67 10 mo GR II Mod 2 1 2 2 3 TURP   
67 65 9 mo GR II Severe 3 1 2 3 1 TURP   
68 65 7 mo GR I Mod 2 1 1 1 3 TURP   
S.No. Age LUTS DRE LUTS score ED EjD Desire Satisfaction Bother Treatment
Post treatment 
ED Ej D 
69 59 6 mo GR I mild 1 1 1 1 5 TURP   
70 62 8 mo GR II Severe 3 2 3 3 1 TURP   
71 65 1 yr GR II Severe 3 1 3 3 1 TURP   
72 60 3 mo GR I Mod 2 1 1 1 5 Medical 2 1 
73 60 8 mo GR II Severe 3 2 2 3 1 TURP   
74 76 10 mo GRIII Severe 2 2 2 2 4 TURP   
75 69 7 mo GR II Severe 2 1 1 1 3 TURP   
76 64 8 mo GR I Severe 3 2 2 2 2 TURP   
77 66 9 mo GR II Mod 2 1 1 2 3 TURP   
78 60 5 mo GR I mild 1 1 1 1 5 TURP 1 2 
79 65 1 yr GR II Severe 3 2 2 3 1 TURP   
80 73 1 yr GR II Severe 3 2 2 3 2 TURP 3 3 
81 69 10 mo GR II Severe 2 1 1 2 3 TURP   
82 70 6 mo GR II Severe 3 2 2 3 3 TURP 3 3 
S.No. Age LUTS DRE LUTS score ED EjD Desire Satisfaction Bother Treatment
Post treatment 
ED Ej D 
83 60 6 mo GR I mild 1 1 1 1 5 Medical 1 1 
84 61 5 mo GR I Mod 2 1 1 2 2 TURP 3 2 
85 64 8 mo GR II Mod 3 2 2 3 1 TURP   
86 58 6 mo GR I Mod 1 1 1 1 5 TURP 1 2 
87 77 9 mo GR II Severe 2 2 2 3 5 TURP   
88 68 4 mo GR II Severe 3 2 2 4 1 TURP 3 2 
89 64 8 mo GR II Severe 3 1 1 4 1 TURP   
90 65 6 mo GR I Mod 2 1 1 1 3 TURP   
91 60 5 mo GR I Mod 1 1 1 1 5 TURP 1 2 
92 60 1 yr GR II Severe 2 1 1 1 4 TURP 3 2 
93 62 10 mo GR II Severe 3 1 1 1 1 TURP   
94 67 8mo GR II Severe 2 2 2 3 1 TURP   
95 55 5 mo GR I mild 1 1 1 1 5 Medical 1 1 
96 60 9 mo GR II Mod 2 1 1 1 4 TURP   
S.No. Age LUTS DRE LUTS score ED EjD Desire Satisfaction Bother Treatment
Post treatment 
ED Ej D 
97 70 1 yr GR II Severe 3 2 2 3 3 TURP   
98 58 6 mo GR I Severe 2 1 1 3 1 TURP   
99 60 6 mo GR I Mod 2 1 1 1 5 TURP   
100 65 8 mo GR II Severe 3 1 1 2 3 TURP   
101 63 18 mo GR II Severe 3 2 2 3 1 TURP   
102 55 7 mo GR I mild 1 1 1 1 5 Medical 1 1 
103 59 5 mo GR I Mod 2 1 1 1 3 TURP   
104 64 9 mo GR II Mod 1 1 1 1 5 Medical 1 1 
105 67 10 mo GR II Severe 2 2 2 3 2 TURP 3 2 
106 65 6 mo GR I Mod 2 1 1 2 4 TURP   
107 59 7 mo GR I Mod 1 1 1 1 5 TURP   
108 73 6 mo GR II Severe 3 2 2 2 5 TURP   
109 64 8 mo GR II Severe 3 1 1 2 2 TURP   
110 66 10 mo GR II Severe 3 2 2 3 1 TURP   
S.No. Age LUTS DRE LUTS score ED EjD Desire Satisfaction Bother Treatment
Post treatment 
ED Ej D 
111 63 6 mo GR II Severe 3 2 3 4 1 TURP   
112 60 5 mo GR I Mod 1 1 1 1 5 Medical 1 1 
113 60 6 mo GR II Mod 2 1 1 1 4 TURP   
114 65 8 mo GR II Mod 2 2 1 3 2 TURP   
115 67 1 yr GR II Severe 3 2 3 4 1 TURP   
116 59 6 mo GR I Mod 2 1 1 2 3 TURP   
117 60 9 mo GR II Severe 3 3 3 4 1 TURP   
118 68 5 mo GR II Severe 3 1 1 2 3 TURP   
119 65 6 mo GR II Severe 2 1 2 2 2 TURP   
120 67 8 mo GR II Severe 3 2 2 3 1 TURP   
 
Code 
Erectile Dysfunction (ED)   EjD – Ejaculatory Dysfunction  Overall Bother 
1 – None    1 – None     1 - Severe 
2 – Moderate Bother   2 – Moderate Bother    2 - Moderate 
3 – Severe Bother   3 – Severe Bother    3 – Small 
           4 – Very Small 
           5 – No Bother  
 
 
 
 
